0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Rheumatic Disorders Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

Rheumatic Disorders Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00 – $ 8,900.00

Rheumatic Disorders Treatment Market: By Disease (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others), By Treatment (Narcotic Analgesics, NSAIDS, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Response Modifiers (Monoclonal Antibodies (mAb), TNF Inhibitors, Interleukin (IL) Inhibitors, JAK inhibitors), and Others), and Geography

 

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,
Report

Description

Rheumatic Disorders Treatment Market size was valued at USD 64.02 billion in 2021, growing at a CAGR of 5.2% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by disease and by treatment. By disease, the global rheumatic disorders treatment market has been segmented into Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others. The Rheumatoid Arthritis segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. It is due to the increasing prevalence of rheumatoid arthritis. Based on treatment, the global rheumatic disorders treatment market is segmented into Narcotic Analgesics, NSAIDS, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Among these, the Disease-Modifying Anti-Rheumatic Drugs (DMARDs) segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. The rise in the incidence of number of indications within the rheumatic disorder’s and increase in prevalence of geriatric population are the major factors that are driving the growth of the market in 2022 and is expected to maintain a significant CAGR in the upcoming years.

Key Development:

In Aug 2022, Lilly completes Phase II rheumatoid arthritis trial successfully.

Rheumatic Disorders Treatment Market

MARKET SUMMARY
-
5.2%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.2%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Rheumatic Disorders Treatment Market

  • Rheumatic disorders treatment market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global rheumatic disorders treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of product and services, application, sector, and region.
Key Players
  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Corbus Pharmaceuticals
Rheumatic Disorders Treatment Market

Drivers and Restraints

Growing geriatric populations, increasing prevalence of rheumatic disorders are anticipated to propel the market growth over the forecast years.

North-America Got Significant Share

Rheumatic Disorders Treatment Market

By region, the North America is expected to witness the highest market share during the forecast period it holds a tremendous potential market for global rheumatic disorder’s treatment.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Rheumatic Disorders Treatment Market Segmentation

segmentation-block-image

Disease

    • Rheumatoid Arthritis
    • Osteoarthritis
    • Osteoporosis
    • Systemic Lupus Erythematosus
    • Psoriatic Arthritis
    • Gout
    • Others
segmentation-block-image

Treatment

    • Narcotic Analgesics
    • NSAIDS
    • Corticosteroids
    • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • Biologic Response Modifiers
      • Monoclonal Antibodies (mAb)
      • TNF Inhibitors
      • Interleukin (IL) Inhibitors (IL)
      • JAK inhibitors
    • Others
segmentation-block-image

Geography

    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East and Africa
Location

GEOGRAPHY

Frequently Asked Questions

The fastest-growing segment of the global rheumatic disorder’s treatment market is Rheumatoid Arthritis due to increasing prevalence of the disease and high demand for treatment and awareness.

The lack of resources for the development of rheumatoid arthritis drugs is the major challenge in underdeveloped nations.

Growing advancements in biologics may provide lucrative opportunity in the global market due to rapid investment in R&D sector.

The lack of awareness and high cost of rheumatoid arthritis drugs may hamper the global market growth.

Report

Table Of Content

  1. Executive Summary
  2. Global Rheumatic Disorders Treatment Market Introduction

2.1. Global Rheumatic Disorders Treatment Market – Taxonomy

2.2. Global Rheumatic Disorders Treatment Market –Definitions

2.2.1. By Disease

2.2.2. By Treatment

2.2.3. By Distribution Channel

  1. Global Rheumatic Disorders Treatment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Rheumatic Disorders Treatment Market Dynamics – Factors Impact Analysis

  1. Global Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Disease, 2014 – 2018 and Forecast, 2019 – 2025

5.1. Rheumatoid Arthritis

5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Osteoarthritis

5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Osteoporosis

5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Systemic Lupus Erythematosus

5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Psoriatic Arthritis

5.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

5.6. Gout

5.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

5.7. Others

5.7.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Treatment, 2014 – 2018 and Forecast, 2019 – 2025

6.1. Narcotic Analgesics

6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. NSAIDS

6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Corticosteroids

6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

6.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

6.5. Biologic Response Modifiers

6.5.1. Monoclonal Antibodies

6.5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.1.3. Market Opportunity Analysis

6.5.2. TNF Inhibitors

6.5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.2.3. Market Opportunity Analysis

6.5.3. Interleukin Inhibitors

6.5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3.3. Market Opportunity Analysis

6.5.4. JAK Inhibitors

6.5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.4.3. Market Opportunity Analysis

6.6. Others

6.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.6.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Distribution Channel, 2014 – 2018 and Forecast, 2019 – 2025

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025

8.1. North America

8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia Pacific

8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. The Middle East & Africa

8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Region, 2019 – 2025

  1. North America Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

9.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Rheumatoid Arthritis

9.1.2. Osteoarthritis

9.1.3. Osteoporosis

9.1.4. Systemic Lupus Erythematosus

9.1.5. Psoriatic Arthritis

9.1.6. Gout

9.1.7. Others

9.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Narcotic Analgesics

9.2.2. NSAIDS

9.2.3. Corticosteroids

9.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

9.2.5. Biologic Response Modifiers

9.2.5.1. Monoclonal Antibodies (mAb)

9.2.5.2. TNF Inhibitors

9.2.5.3. Interleukin (IL) Inhibitors (IL)

9.2.5.4. JAK inhibitors

9.2.6. Others

9.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

9.6. North America Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Europe Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

10.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Rheumatoid Arthritis

10.1.2. Osteoarthritis

10.1.3. Osteoporosis

10.1.4. Systemic Lupus Erythematosus

10.1.5. Psoriatic Arthritis

10.1.6. Gout

10.1.7. Others

10.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Narcotic Analgesics

10.2.2. NSAIDS

10.2.3. Corticosteroids

10.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

10.2.5. Biologic Response Modifiers

10.2.5.1. Monoclonal Antibodies (mAb)

10.2.5.2. TNF Inhibitors

10.2.5.3. Interleukin (IL) Inhibitors (IL)

10.2.5.4. JAK inhibitors

10.2.6. Others

10.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. U.K.

10.4.2. Germany

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Europe Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

10.6. Europe Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Asia Pacific Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

11.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Rheumatoid Arthritis

11.1.2. Osteoarthritis

11.1.3. Osteoporosis

11.1.4. Systemic Lupus Erythematosus

11.1.5. Psoriatic Arthritis

11.1.6. Gout

11.1.7. Others

11.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Narcotic Analgesics

11.2.2. NSAIDS

11.2.3. Corticosteroids

11.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

11.2.5. Biologic Response Modifiers

11.2.5.1. Monoclonal Antibodies (mAb)

11.2.5.2. TNF Inhibitors

11.2.5.3. Interleukin (IL) Inhibitors (IL)

11.2.5.4. JAK inhibitors

11.2.6. Others

11.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. ASEAN Counties

11.4.5. Philippines

11.4.6. Rest of Asia Pacific

11.5. Asia Pacific Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

11.6. Asia Pacific Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Latin America Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

12.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Rheumatoid Arthritis

12.1.2. Osteoarthritis

12.1.3. Osteoporosis

12.1.4. Systemic Lupus Erythematosus

12.1.5. Psoriatic Arthritis

12.1.6. Gout

12.1.7. Others

12.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Narcotic Analgesics

12.2.2. NSAIDS

12.2.3. Corticosteroids

12.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

12.2.5. Biologic Response Modifiers

12.2.5.1. Monoclonal Antibodies (mAb)

12.2.5.2. TNF Inhibitors

12.2.5.3. Interleukin (IL) Inhibitors (IL)

12.2.5.4. JAK inhibitors

12.2.6. Others

12.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Mexico

12.4.2. Brazil

12.4.3. Argentina

12.4.4. Chile

12.4.5. Rest of Latin America

12.5. Latin America Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

12.6. Latin America Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Middle East and Africa Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

13.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Rheumatoid Arthritis

13.1.2. Osteoarthritis

13.1.3. Osteoporosis

13.1.4. Systemic Lupus Erythematosus

13.1.5. Psoriatic Arthritis

13.1.6. Gout

13.1.7. Others

13.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Narcotic Analgesics

13.2.2. NSAIDS

13.2.3. Corticosteroids

13.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

13.2.5. Biologic Response Modifiers

13.2.5.1. Monoclonal Antibodies (mAb)

13.2.5.2. TNF Inhibitors

13.2.5.3. Interleukin (IL) Inhibitors (IL)

13.2.5.4. JAK inhibitors

13.2.6. Others

13.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Saudi Arabia

13.4.4. Turkey

13.4.5. Rest of MEA

13.5. Middle East and Africa Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

13.6. Middle East and Africa Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis)

14.2.1. AbbVie

14.2.2. Amgen

14.2.3. Astellas

14.2.4. AstraZeneca

14.2.5. Bristol-Myers Squibb

14.2.6. ChemoCentryx

14.2.7. Corbus Pharmaceuticals

14.2.8. Eli Lilly

14.2.9. Gilead Sciences

14.2.10. GlaxoSmithKline

14.2.11. Johnson & Johnson

14.2.12. Novartis

14.2.13. Pfizer

14.2.14. Roche

14.2.15. Selecta Biosciences

14.2.16. UCB

  1. Research Methodology
  2. Key Assumptions and Acronyms
Report

Company Profile

  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • ChemoCentryx
  • Corbus Pharmaceuticals
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche
  • Selecta Biosciences
  • UCB

Description

Rheumatic Disorders Treatment Market size was valued at USD 64.02 billion in 2021, growing at a CAGR of 5.2% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by disease and by treatment. By disease, the global rheumatic disorders treatment market has been segmented into Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others. The Rheumatoid Arthritis segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. It is due to the increasing prevalence of rheumatoid arthritis. Based on treatment, the global rheumatic disorders treatment market is segmented into Narcotic Analgesics, NSAIDS, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Among these, the Disease-Modifying Anti-Rheumatic Drugs (DMARDs) segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. The rise in the incidence of number of indications within the rheumatic disorder’s and increase in prevalence of geriatric population are the major factors that are driving the growth of the market in 2022 and is expected to maintain a significant CAGR in the upcoming years.

Key Development:

In Aug 2022, Lilly completes Phase II rheumatoid arthritis trial successfully.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+